A high-performance microsystem for isolating circulating tumor cells.

A unique flow field pattern in a bio-functional microchannel is utilized to significantly enhance the performance of a microsystem developed for selectively isolating circulating tumor cells from cell suspensions. For high performance of such systems, disposal of maximum non-target species is just as important as retention of maximum target species; unfortunately, most studies ignore or fail to report this aspect. Therefore, sensitivity and specificity are introduced as quantitative criteria to evaluate the system performance enabling a direct comparison among systems employing different techniques. The newly proposed fluidic scheme combines a slow flow field, for maximum target-cell attachment, followed by a faster flow field, for maximum detachment of non-target cells. Suspensions of homogeneous or binary mixtures of circulating breast tumor cells, with varying relative concentrations, were driven through antibody-functionalized microchannels. Either EpCAM or cadherin-11 transmembrane receptors were targeted to selectively capture target cells from the suspensions. Cadherin-11-expressing MDA-MB-231 cancer cells were used as target cells, while BT-20 cells were used as non-target cells as they do not express cadherin-11. The attachment and detachment of these two cell lines are characterized, and a two-step attachment/detachment flow field pattern is implemented to enhance the system performance in capturing target cells from binary mixtures. While the system sensitivity remains high, above 0.95, the specificity increases from about 0.85 to 0.95 solely due to the second detachment step even for a 1 : 1000 relative concentration of the target cells.

[1]  J. Witte,et al.  Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Springer,et al.  Neutrophils roll on E-selectin. , 1993, Journal of immunology.

[3]  Kristine R Broglio,et al.  Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. , 2007, Clinical breast cancer.

[4]  Mehmet Toner,et al.  A microfluidic device for practical label-free CD4(+) T cell counting of HIV-infected subjects. , 2007, Lab on a chip.

[5]  Lap Man Lee,et al.  Low melting point agarose as a protection layer in photolithographic patterning of aligned binary proteins. , 2006, Lab on a chip.

[6]  Milica Radisic,et al.  Microfluidic depletion of endothelial cells, smooth muscle cells, and fibroblasts from heterogeneous suspensions. , 2008, Lab on a chip.

[7]  T. Yagi,et al.  Cadherin superfamily genes: functions, genomic organization, and neurologic diversity. , 2000, Genes & development.

[8]  Keith R. Johnson,et al.  N-Cadherin Promotes Motility in Human Breast Cancer Cells Regardless of Their E-Cadherin Expression , 1999, The Journal of cell biology.

[9]  Xiangjun Zheng,et al.  Kinematics of Specifically Captured Circulating Tumor Cells in Bio-Functionalized Microchannels , 2010, Journal of Microelectromechanical Systems.

[10]  D. A. Hammer,et al.  Receptor-mediated binding of IgE-sensitized rat basophilic leukemia cells to antigen-coated substrates under hydrodynamic flow. , 1994, Biophysical journal.

[11]  Xiangjun Zheng,et al.  Adhesion dynamics of circulating tumor cells under shear flow in a bio-functionalized microchannel , 2011 .

[12]  S. Digumarthy,et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.

[13]  D. Bostwick,et al.  Ep-Cam levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. , 1999, The Journal of urology.

[14]  D. Altman,et al.  Statistics Notes: Diagnostic tests 1: sensitivity and specificity , 1994 .

[15]  C. Rubio,et al.  The tumor-associated antigens BR55-2, GA73-3 and GICA 19-9 in normal and corresponding neoplastic human tissues, especially gastrointestinal tissues. , 1989, Anticancer Research.

[16]  S. Troyanovsky,et al.  Mechanism of cell-cell adhesion complex assembly. , 1999, Current opinion in cell biology.

[17]  S. Braun,et al.  Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  Paul I. Okagbare,et al.  Highly efficient circulating tumor cell isolation from whole blood and label-free enumeration using polymer-based microfluidics with an integrated conductivity sensor. , 2008, Journal of the American Chemical Society.

[19]  M. Steurer,et al.  Correlation of COX-2 and Ep-CAM overexpression in human invasive breast cancer and its impact on survival , 2003, British Journal of Cancer.

[20]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[21]  P. Robinson,et al.  Increased expression of a 38kd cell-surface glycoprotein MH99 (KS 1/4) in oral mucosal dysplasias. , 1996, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[22]  D. Hammer,et al.  Lifetime of the P-selectin-carbohydrate bond and its response to tensile force in hydrodynamic flow , 1995, Nature.

[23]  B. Wollenberg,et al.  Tumor-specific glycosylation of the carcinoma-associated epithelial cell adhesion molecule EpCAM in head and neck carcinomas. , 2003, Cancer letters.

[24]  D. Hayes,et al.  The measurement and therapeutic implications of circulating tumour cells in breast cancer , 2005, British Journal of Cancer.

[25]  J. V. van Krieken,et al.  Expression of Ep‐CAM in normal, regenerating, metaplastic, and neoplastic liver , 1999, The Journal of pathology.

[26]  S. Litvinov,et al.  The biology of the 17–1A antigen (Ep-CAM) , 1999, Journal of Molecular Medicine.

[27]  Keith R. Johnson,et al.  Cadherins as modulators of cellular phenotype. , 2003, Annual review of cell and developmental biology.

[28]  Dorian Liepmann,et al.  Biomimetic technique for adhesion-based collection and separation of cells in a microfluidic channel. , 2005, Lab on a chip.

[29]  D. Hammer,et al.  Simulation of cell rolling and adhesion on surfaces in shear flow: general results and analysis of selectin-mediated neutrophil adhesion. , 1992 .

[30]  James C Baygents,et al.  Detachment of captured cancer cells under flow acceleration in a bio-functionalized microchannel. , 2009, Lab on a chip.

[31]  Y. Hannun,et al.  EpCAM Is Overexpressed in Breast Cancer and Is a Potential Target for Breast Cancer Gene Therapy , 2004, Cancer Research.

[32]  T. Fehm,et al.  Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells , 2009, Breast Cancer Research.

[33]  S. Byers,et al.  Cadherin-11 is expressed in invasive breast cancer cell lines. , 1999, Cancer research.

[34]  N. Tran,et al.  Signal Transduction from N-cadherin Increases Bcl-2 , 2002, The Journal of Biological Chemistry.

[35]  J. Murray,et al.  Monoclonal antibody therapy for solid tumors. , 2000, Cancer treatment reviews.

[36]  Claire Holloway,et al.  Enumeration of Circulating Tumor Cells in the Blood of Breast Cancer Patients After Filtration Enrichment: Correlation with Disease Stage , 2004, Breast Cancer Research and Treatment.

[37]  B. Gumbiner,et al.  Molecular and functional analysis of cadherin-based adherens junctions. , 1997, Annual review of cell and developmental biology.

[38]  M. Peters,et al.  Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines , 2005, British Journal of Cancer.